Kindred Biosciences (KIN) Short Interest Ratio & Short Volume → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free KIN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Kindred Biosciences Short Interest DataCurrent Short Volume921,200 sharesPrevious Short Volume979,300 sharesChange Vs. Previous Month-5.93%Dollar Volume Sold Short$8.49 millionShort Interest Ratio / Days to Cover0.6Last Record DateAugust 13, 2021Outstanding Shares45,462,000 sharesFloat Size36,410,000 sharesShort Percent of Float2.53%Today's Trading Volume178,496 sharesAverage Trading Volume840,890 sharesToday's Volume Vs. Average21% Short Selling Kindred Biosciences ? Sign up to receive the latest short interest report for Kindred Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKIN Short Interest Over TimeKIN Days to Cover Over TimeKIN Percentage of Float Shorted Over Time Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. Kindred Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/13/2021921,200 shares $8.49 million -5.9%2.5%0.6 $9.22 7/30/2021979,300 shares $8.93 million -4.9%2.7%0.7 $9.12 7/15/20211,030,000 shares $9.41 million -15.6%2.8%0.8 $9.14 6/30/20211,220,000 shares $11.19 million -32.6%3.4%1 $9.17 6/15/20211,810,000 shares $11.48 million +24.0%N/A1.6 $6.34 5/28/20211,460,000 shares $7.05 million +4.3%N/A3.2 $4.83 Get the Latest News and Ratings for KIN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. 5/14/20211,400,000 shares $5.91 million +9.4%N/A3.9 $4.22 4/30/20211,280,000 shares $6.13 million +14.3%N/A3.3 $4.79 4/15/20211,120,000 shares $5.57 million -2.6%2.9%2.3 $4.97 3/31/20211,150,000 shares $5.21 million +6.5%3.0%2.4 $4.53 3/15/20211,080,000 shares $5.29 million -1.8%2.8%2.5 $4.90 2/26/20211,100,000 shares $5.05 million +10.8%3.0%2.7 $4.59 2/12/2021992,500 shares $5.20 million +21.6%2.7%2.7 $5.24 1/29/2021816,000 shares $4.08 million +10.1%2.2%2.3 $5.00 1/15/2021740,900 shares $3.70 million -2.5%2.0%3 $5.00 12/31/2020760,000 shares $3.25 million +6.6%2.1%3.5 $4.28 12/15/2020712,700 shares $2.86 million +3.0%1.9%3.2 $4.01 11/30/2020692,000 shares $2.70 million +2.0%1.9%3.2 $3.90 11/15/2020678,200 shares $2.54 million +1.8%1.8%2.4 $3.75 10/30/2020666,300 shares $2.47 million +7.4%1.8%2.3 $3.70 10/15/2020620,500 shares $2.72 million +5.7%1.7%2 $4.38 9/30/2020587,000 shares $2.52 million -4.1%1.6%1.9 $4.29 9/15/2020611,800 shares $2.81 million +0.1%1.7%1.6 $4.59 8/31/2020611,200 shares $3.03 million +3.0%1.7%1.6 $4.96 8/14/2020593,400 shares $2.40 million -14.9%1.6%1.5 $4.04 7/31/2020696,900 shares $2.29 million +9.1%1.9%1.6 $3.29 7/15/2020638,600 shares $2.62 million +28.2%1.7%1.5 $4.11 6/30/2020498,000 shares $2.24 million +3.9%1.4%1.2 $4.49 6/15/2020479,400 shares $2.15 million -6.8%1.3%1.4 $4.48 5/29/2020514,600 shares $2.21 million +19.0%1.4%1.5 $4.29 5/15/2020432,600 shares $2.09 million +12.8%1.2%1.6 $4.82 4/30/2020383,500 shares $1.93 million -12.3%1.0%1.7 $5.02 4/15/2020437,100 shares $1.85 million +0.4%1.2%2.2 $4.24 3/31/2020435,500 shares $1.74 million -18.5%1.2%2.1 $3.99 3/13/2020534,100 shares $2.21 million -11.4%1.5%2.9 $4.14 2/28/2020602,900 shares $1.97 million -5.7%1.6%4 $3.26 2/14/2020639,100 shares $6.00 million -1.3%1.7%4.9 $9.39 1/31/2020647,300 shares $6.53 million -14.0%1.8%5.1 $10.09 1/15/2020753,000 shares $6.94 million +16.2%2.1%6 $9.22 12/31/2019648,200 shares $6.16 million -3.4%1.8%5.3 $9.50AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. KIN Short Interest - Frequently Asked Questions What is Kindred Biosciences' current short interest? Short interest is the volume of Kindred Biosciences shares that have been sold short but have not yet been closed out or covered. As of August 13th, investors have sold 921,200 shares of KIN short. 2.53% of Kindred Biosciences' shares are currently sold short. Learn More on Kindred Biosciences' current short interest. What is a good short interest ratio for Kindred Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KIN shares currently have a short interest ratio of 1.0. Learn More on Kindred Biosciences's short interest ratio. What is a good short interest percentage for Kindred Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.53% of Kindred Biosciences' floating shares are currently sold short. Is Kindred Biosciences' short interest increasing or decreasing? Kindred Biosciences saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 921,200 shares, a decrease of 5.9% from the previous total of 979,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Kindred Biosciences' float size? Kindred Biosciences currently has issued a total of 45,462,000 shares. Some of Kindred Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Kindred Biosciences currently has a public float of 36,410,000 shares. How does Kindred Biosciences' short interest compare to its competitors? 2.53% of Kindred Biosciences' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Kindred Biosciences: Shattuck Labs, Inc. (4.01%), Akebia Therapeutics, Inc. (4.84%), Harrow Health, Inc. (15.55%), PepGen Inc. (1.31%), Theravance Biopharma, Inc. (18.93%), Heron Therapeutics, Inc. (16.92%), Avid Bioservices, Inc. (17.14%), Terns Pharmaceuticals, Inc. (10.68%), Arbutus Biopharma Co. (2.30%), ESSA Pharma Inc. (4.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Block, Inc. ($9.67 billion), S&P Global Inc. ($7.87 billion), Advanced Micro Devices, Inc. ($7.80 billion), Analog Devices, Inc. ($7.03 billion), Sea Limited ($6.40 billion), Charter Communications, Inc. ($5.60 billion), Wayfair Inc. ($5.18 billion), Aon plc ($3.93 billion), CrowdStrike Holdings, Inc. ($2.52 billion), and Teladoc Health, Inc. ($2.49 billion). View all of the most shorted stocks. What does it mean to sell short Kindred Biosciences stock? Short selling KIN is an investing strategy that aims to generate trading profit from Kindred Biosciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kindred Biosciences? A short squeeze for Kindred Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KIN, which in turn drives the price of the stock up even further. How often is Kindred Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KIN, twice per month. The most recent reporting period available is August, 13 2021. More Short Interest Resources from MarketBeat Related Companies: STTK Short Interest Data AKBA Short Interest Data HROW Short Interest Data PEPG Short Interest Data TBPH Short Interest Data HRTX Short Interest Data CDMO Short Interest Data TERN Short Interest Data ABUS Short Interest Data EPIX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KIN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research